Volume 22, Number 7—July 2016
Dispatch
Identification of Streptococcus suis Meningitis through Population-Based Surveillance, Togo, 2010–2014
Table 2
Antimicrobial drug | No. S. suis samples tested/no. (%) susceptible |
No. other Streptococcus spp. samples tested/no. (%) susceptible | |
---|---|---|---|
Tested at local laboratory* | Tested at reference laboratory† | ||
Amoxicillin | 15/15 (100) | 11/10 (91) | 9/5 (56) |
Cefotaxime | 0 | 11/10 (91) | 0 |
Ceftriaxone | 15/15 (100) | 0 | 9/8 (89) |
Chloramphenicol | 15/12 (80) | 11/11 (100) | 9/8 (89) |
Clindamycin | 0 | 11/10 (91) | 0 |
Cotrimoxazole | 15/14 (93) | 0 | 9/6 (67) |
Gentamicin | 15/7 (47) | 0 | 9/4 (44) |
Levofloxacin | 0 | 11/10 (91) | 0 |
Oxacillin | 12/3 (25) | 11/11 (100) | 1/0 |
Penicillin | 15/15 (100) | 11/10 (91) | 9/5 (56) |
Rifampin | 15/15 (100) | 0 | 9/6 (67) |
Tetracycline | 0 | 11/0 | 0 |
*The regional bacteriology laboratory in Dapaong, Togo.
†National Reference Center for Streptococci in Aachen, Germany.
Page created: June 14, 2016
Page updated: June 14, 2016
Page reviewed: June 14, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.